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Abstract
Background: Tumorigenesis requires multiple genetic changes. Mutator mutations are mutations that increase genomic
instability, and according to the mutator hypothesis, accelerate tumorigenesis by facilitating oncogenic mutations.
Alternatively, repeated lineage selection and expansion without increased mutation frequency may explain observed cancer
incidence. Mutator lineages also risk increased deleterious mutations, leading to extinction, thus providing another
counterargument to the mutator hypothesis. Both selection and extinction involve changes in lineage fitness, which may be
represented as ‘‘trajectories’’ through a ‘‘fitness landscape’’ defined by genetics and environment.
Methodology/Principal Findings: Here I systematically analyze the relative efficiency of tumorigenesis with and without
mutator mutations by evaluating archetypal fitness trajectories using deterministic and stochastic mathematical models. I
hypothesize that tumorigenic mechanisms occur clinically in proportion to their relative efficiency. This work quantifies the
relative importance of mutator pathways as a function of experimentally measurable parameters, demonstrating that
mutator pathways generally enhance efficiency of tumorigenesis. An optimal mutation rate for tumor evolution is derived,
and shown to differ from that for species evolution.
Conclusions/Significance: The models address the major counterarguments to the mutator hypothesis, confirming that
mutator mechanisms are generally more efficient routes to tumorigenesis than non-mutator mechanisms. Mutator
mutations are more likely to occur early, and to occur when more oncogenic mutations are required to create a tumor.
Mutator mutations likely occur in a minority of premalignant lesions, but these mutator premalignant lesions are
disproportionately likely to develop into malignant tumors. Tumor heterogeneity due to mutator mutations may contribute
to therapeutic resistance, and the degree of heterogeneity of tumors may need to be considered when therapeutic
strategies are devised. The model explains and predicts important biological observations in bacterial and mouse systems,
as well as clinical observations.
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Introduction
Tumorigenesis is a multistep process [1–5], likely including
genetic mutations in oncogenes and tumor suppressor genes.
The mutator hypothesis states that mutations leading to
enhanced genomic instability (termed ‘‘mutator mutations’’) drive
cancer pathogenesis by accelerating the acquisition of oncogenic
mutations. Originally formulated around DNA polymerases and
repair enzymes [6], the mutator hypothesis has been broadened to
include microsatellite instability, chromosomal instability, and
deficits in checkpoint activation [7–10]. Although mutator
mutations have been found in the germline in certain familial
cancer syndromes [7–8], the generalized mutator hypothesis
focuses on somatic mutator mutations occurring as a step in the
evolution of somatic cells towards malignancy.
On the contrary, it has been argued that mutator mutations
(MM) are unnecessary for cancer development, and that the
observed incidence rates of cancer may be explained by mutations
occurring at the normal rate in conjunction with multiple rounds
of lineage expansion and selection [11–14]. The debate concern-
ing the relevance of the mutator hypothesis has centered around
whether mutator mechanisms are required to explain the
appearance of a single cancer cell within a human lifetime.
A novel approach was recently suggested, based on the wider
perspective that all potential mechanisms of tumorigenesis are in
play, but those which produce malignant lineages most efficiently
are most likely to contribute to clinical cancers [15]. Efficiency is
defined as the expected number of malignant lineages generated
up to and including a reference timepoint by any particular
tumorigenic mechanism. This shifts the issue from analyzing the
waiting time to a single cancer cell, and fitting it to epidemiologic
data, to the evaluation of the relative efficiencies of mutator and non-
mutator pathways in cancer lineage production.
In this framework, mutator mutations, lineage expansion, and
selection are not mutually exclusive and could all simultaneously
contribute to tumorigenesis. It is also noted that the conversion
rate of normal cells to cancer cells (‘‘cancer lineage birth rate’’)
likely far outstrips the number of clinically observed cancers, due
to numerous malignant and premalignant lineages being elimi-
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or competition from other premalignant lineages. Thus models
which match the cancer lineage birth rate to clinical cancer
incidence may have inherent limitations. It may be more relevant
to evaluate the potential contribution of mutator mutations to the
efficiency of tumorigenesis, as opposed to whether mutator
mutations are necessary to explain a rate of cancer lineage birth
rate equal to that of clinically observed cancer incidence.
Furthermore, attempts to compare absolute theoretical cancer
rates to absolute observed cancer rates are very sensitive to the
underlying parameters and other assumptions, leading to variabil-
ity in conclusions [16], whereas in the calculation of relative
efficiencies, many parameters cancel in the ratios, minimizing the
danger of overfitting of models and providing the potential for
more robust conclusions. It is assumed in these models that any
given malignant lineage has an approximately constant and low
probability of developing into a clinical cancer.
An analysis of the relative efficiency of tumorigenesis with and
without a somatic mutator mutation, in the absence of lineage
expansion (LE), demonstrated that mutator mutations enhance
tumorigenic efficiency under many realistic scenarios, despite the
need for an extra mutation step to acquire the mutator mutation
itself [15]. Mutator mutations generally do not enhance efficiency
for cancers whose pathogenesis requires only two genetic
alterations, but increase dramatically in importance as the number
of steps in tumorigenesis increases. However, as the model did not
explicitly include lineage selection and expansion, the question of
the contribution of mutator mutations to tumorigenic efficiency in
the presence of lineage selection and expansion remained open.
Mutator lineages are also more likely to suffer deleterious
mutations that reduce their fitness and potentially lead to
extinction. This effect has been termed negative clonal selection
(NCS) [17]. To date, no analysis of this effect integrated with
simultaneous genetic evolution of the tumor has been performed.
In order to account for the effects of selection and expansion of
fitter lineages, as well as negative clonal selection, I systematically
consider the fitness landscape, or the multidimensional space
representing cellular fitness, as a function of cellular genetic
makeup within an environmental context. Pathways through this
fitness landscape are termed fitness trajectories. Trajectories of special
interest for tumorigenesis are those which begin with a normal cell
and end with a transformed malignant cell.
This paper presents mathematical models which represent the
general case of tumorigenesis across a variety of fitness trajectories,
including multiple situations where the mutator lineage suffers
reduced fitness (NCS), or achieves increased fitness leading to
lineage expansion (LE). Four cases (‘‘fitness trajectories’’), which
differ in the fitness of intermediate lineages in the tumorigenic
process (Figure 1), are considered for both mutator and non-
mutator pathways with respect to the production or birth rate of
new malignant lineages. In order to become a malignant lineage, a
normal lineage must accumulate a fixed number of oncogenic
mutations (hits). Lineages with less than the full complement of
oncogenic mutations may still expand their relative numbers, or
risk extinction, according to their relative fitness, on a continuous
basis throughout the process. The cases differ with respect to the
assumed fitness trajectory, i.e. the relative change in fitness with
each successive oncogenic mutation (Figure 1).
In case 1, the incremental lineage expansion case, the lineages
acquire a fixed increment in fitness with each successive oncogenic
mutation, finally achieving their maximum fitness when they have
acquired a full complement of oncogenic mutations. Given that
most of the increased tumorigenic efficiency due to a mutator
mutation can be captured by the case in which the mutator
mutation is an initial step [15], we focus in the mutator pathway
analysis for case 1 on mutator mutations occurring as an initial
step. In case 2, the cooperative lineage expansion case with early
mutator mutation, there is no increase in fitness until a subset of
oncogenic mutations have been acquired, at which point the
fitness increases rapidly and lineage expansion begins. Additional
oncogenic mutations may then be required to achieve the fully
malignant phenotype. The mutator mutation occurs early, e.g. at
any point before the lineage expansion. In case 3, the cooperative
lineage expansion case with late mutator mutation, the situation is
analogous to case 2 except that the mutator mutation occurs after
the onset of lineage expansion, during the period when additional
oncogenic mutations are occurring towards reaching a fully
malignant phenotype. Since cases 2 and 3 are alternate mutually
exclusive subsets of the same fitness trajectory, their relative
efficiencies (compared to non-mutator pathways) are additive. In
case 4, the mutator and wild type lineages are subject to negative
clonal selection [17]. The lineages have a subset of loci (reduced
fitness or ‘‘RF’’ loci), mutation of which may lead to reduction in
fitness, depending on the genetic and environmental context.
When a reduced fitness locus is mutated, the lineage is at risk for
fitness reduction. Lineages with fitness reduction become extinct,
thus potentially limiting the advantage conferred by a mutator
mutation.
While cases can be proposed that are mixtures of these four
cases, it should be possible to infer their properties once these four
archetypal fitness trajectories are analyzed. Thus, based on
analysis of these pathways in combination (together with the
constant fitness pathway previously analyzed [15]), any conceiv-
able fitness landscape could be analyzed.
Using these models, I evaluate the relative contribution of
mutator mechanisms to tumorigenesis, considering in a quantita-
tive fashion those issues which have historically been raised as
counterarguments to the mutator hypothesis, and demonstrating
predominance of mutator pathways in most instances.
In addition, in the presence of negative clonal selection, I find
an optimal mutation rate for tumor evolution, which appears to
differ from that for species evolution.
The models are focused on enhanced single base substitution
rates, and it would be of interest to specifically model other forms
of genetic instability that might lead to deletions or to
chromosomal instability.
The analysis raises several provocative questions:
1. As mutator pathways appear to predominate in most instances,
can the diversity and complexity of tumors be addressed by
current therapeutic strategies?
2. Can tumor diversity and genetic instability be used to stratify
patients for prognosis and therapy?
3. Can therapy be designed to increase the mutation rate in
tumors beyond the optimum derived in this paper, resulting in
lethal mutagenesis?
4. Can the onset of tumors be delayed to beyond the human
lifetime, and therefore prevented, by small decreases in the
mutation rate?
5. What are the underlying reasons for quantitative differences
between tumor and species evolution?
Results
Model outputs
The results for the four cases below are presented in terms of
two key model outputs: (1) relative tumorigenic efficiency of
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increase in mutation rate required from a mutator mutation before
the mutator pathway has a relative tumorigenic efficiency greater
than or equal to 1, termed a50%.
Nrel is the ratio of malignant lineages produced by mutator and
non-mutator pathways under the specified conditions. The
fraction of clinical cancers arising by mutator pathways is given
by Nrel/(1+Nrel), and mutator mechanisms predominate if Nrel.1.
In non-lineage expansion models, in which progression to a
malignant lineage is a rare event, Nrel can be expressed as a ratio
of probabilities, Prel [15].
a is the multiplicative factor by which a mutator mutation
increases the somatic mutation rate per cell generation, e.g. the
magnitude of the genetic instability. In the lineage expansion
(cases 1–3) and constant fitness [15] models, there is a minimum
value of a, which we term a50%, at which mutator pathways are
expected to contribute to half of clinical cancers, and above which
mutator pathways predominate. The fraction of total cancers
caused by a mutator pathway with a given a when compared to an
alternative non-mutator pathway is given by a
C/(a
C+a50%
C),
where C is the number of oncogenic mutations required for
malignant transformation. Thus, a mutator mutation must confer
a minimum level of genetic instability to be relevant. In evaluating
the importance of mutator pathways in a particular model, we
need to determine if a50% is within a range commonly seen in
known mutator mutations.
Mutations in base selection and proofreading generally increase
mutation rates 10–100 fold [18–19], and increased random
mutation frequencies of up to 500-fold have recently been
observed in human tumors [20]. In evaluating the results below,
mutator pathways are expected to predominate when a50% is at or
below commonly observed values of a (ca. 10–500).
For the negative clonal selection model (case 4), an additional
key output is an optimal value of the fold increase in mutation rate,
Figure 1. Representative fitness landscapes for tumorigenesis. R, the natural logarithm of the relative fitness advantage compared to wild
type, is plotted as a function of number of oncogenic mutations for each of the four fitness landscapes considered in this paper (pink lines), relative to
the constant fitness case (green lines) [15]. Positive and negative values of R correspond to increased and decreased fitness respectively. In this figure,
it is assumed that C oncogenic mutations are required for malignant transformation, at which point the lineage acquires markedly increased fitness
relative to wild type. A, Case 1: incremental lineage expansion (LE). The relative fitness increases incrementally with each oncogenic mutation. B, Case
2: cooperative lineage expansion with early mutator mutation (MM). Fitness increases suddenly and cooperatively after a predefined number, D,C,
of oncogenic mutations, prior to malignant transformation after C mutations. In the mutator pathway, the mutator mutation occurs before the
sudden increase in fitness, within the time bounded by the arrows. C, Case 3: cooperative lineage expansion (LE) with late mutator mutation (MM). As
in B, except in the mutator pathway the mutator mutation occurs after the sudden fitness increase, within the time bounded by the arrows. D, Case 4:
negative clonal selection (NCS). The lineage acquires oncogenic mutations, while the fitness continuously decreases due to accumulated random
deleterious mutations. The fitness of the lineage increases only if it reaches full malignant transformation.
doi:10.1371/journal.pone.0005860.g001
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This corresponds to an optimal mutation rate, kmut-optimal.
Model inputs
The results depend on the properties of the tumor under
consideration, which in turn define the inputs to the models. The
key input parameters for all the models are: C, the number of
oncogenic mutations required for transformation to the malignant
phenotype; R$0, the natural logarithm of the relative fitness of a
malignant cell compared to wild type (meaning that with each
successive generation the relative numbers of the malignant
lineage increase by a factor e
R); 0#Rp#R, the component of R
which is due to enhanced proliferation (the remainder would be
due to decreased apoptosis); T, the time (in cell generations) to
malignancy; NML, the number of genomic ‘‘mutator loci’’, in
nucleotides, mutation of which leads to genetic instability; and
kmut, the mutation rate per nucleotide base per cell generation in
wild type cells.
In the cooperative lineage expansion models (cases 2 and 3), an
additional input parameter is introduced: D, the number of
oncogenic mutations required for an increase in fitness. In the
negative clonal selection model (case 4), I introduce the input
parameter NRFLN-D (Nreduced fitness loci net-dominant), which is an
indicator of the vulnerability of the genome to mutations which
may reduce cellular fitness [17]. It consists of the number of loci, in
base pairs, single copy mutation of which may reduce fitness of the
lineage, where the loci are divided into subclasses, and the number
in each subclass is multiplied by the probability that a mutation of
it will lead to a fitness reduction as a function of genetic and
environmental context.
Key input parameters and the ranges over which they have
been varied in the calculations, as well as key model outputs, are
summarized in Table 1. The remainder of this section describes
selected results and their dependence on input parameters. Further
detailed results, not shown in the Figures, are given in
Supplementary Tables.
In the calculations, I assume NML is 100, a very conservative
assumption [15,21]. If NML=1000, a50% would decrease by a
factor of 10
1/C (relative to the same case with NML=100), further
enhancing the potential role of mutator pathways.
Using the equations in Methods, one may rapidly explore a
wide variety of other questions and input parameters.
Case 1: incremental lineage expansion
In analyzing this case, we assume that C oncogenic mutations
are required for transformation to the malignant phenotype (C
generally varying between 2 and 12 based on epidemiologic data
of cancer incidence as a function of age [22]), that a malignant cell
has increased fitness R relative to wild type (meaning that with
each successive generation the relative numbers of the malignant
lineage increase by a factor e
R), and each successive oncogenic
mutation leads to an incremental increase in fitness R/C (Fig. 1A).
Based on the previous finding that the major component of
efficiency in mutator pathways is due to initial mutator mutations
[15], we evaluate the mutator pathway assuming the mutator
mutation occurs first. We find in this case that multiple lineages
are simultaneously expanding at different exponential rates,
corresponding to lineages with 1, 2, … C21 oncogenic mutations,
and therefore incrementally different fitness. Thus the full
expression for the number of malignant cells generated by either
Table 1. Input and output parameters for models.
Parameter Definition Applicability Range References
3
NOL Number of oncogenic loci
1 Input, all models 100 15
C Number of oncogenic mutations required for
malignant transformation
Input, all models 2–12 15, 22
D Number of oncogenic mutations required for
cooperative fitness increase
Input, cooperative lineage expansion
models (cases 2 and 3)
1–6 NA
kmut Wild type mutation rate
2 Input, all models 10
211–10
29 15,17
T Number of cell generations to cancer Input, all models 170–5000 15,17
NML Number of loci available for mutator mutations
1 Input, all models 100–1000 15
a Fold increase in mutation rate due to mutator mutation Input, all models 1–‘ (commonly 10–500) 15, 18, 22
R Log of relative fitness advantage for malignant cells Input, lineage expansion models (cases 1–3) 0–2 NA
RP Log of relative fitness advantage due to proliferation Input, lineage expansion models (cases 1–3) 0–1.31 Tables S1–S2
NRFLN-D Indicator of vulnerability of genome to dominant
reduced fitness mutations
Input, negative clonal selection model
(case 4)
0–9.8610
5 17
Nrel Relative efficiency of mutator pathways compared to
non-mutator pathways
Output, all models NA NA
Prel Relative probability of mutator pathways compared
to non-mutator pathways
Output, constant fitness model and
negative clonal selection model (case 4)
NA 15
a50% Minimal fold increase in mutation rate corresponding
to at least equal efficiency of mutator and
non-mutator pathways
Output, constant fitness and lineage
expansion models (cases 1–3)
NA 15
kmut-optimal Optimal mutation rate for tumor evolution Output, negative clonal selection model
(case 4)
NA NA
1in nucleotide bases.
2per nucleotide base, per wild type cell generation.
3references where parameter is explained or its reference range is justified; NA, not applicable.
doi:10.1371/journal.pone.0005860.t001
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expressions by the highest order term (i.e. the most rapidly
growing exponential), representing the pool of cells with C21
oncogenic mutations from which the new malignant lineages are
drawn by one more mutation, we obtain several results
(Supplementary Tables S1 and S2 and Figure 2). a50% is
calculated using equations[11–12], and Nrel by equation [13], in
Methods.
Firstly, mutator mechanisms predominate in most instances,
although the value of a50% increases slightly compared to the
constant fitness case (Supplementary Table S1 and Figure 2). For
most parameter values in case 1, a50% remains within the range of
a for commonly observed mutator mutations, indicating that
mutator pathways will have a significant role in tumorigenesis.
The relative importance of mutator pathways in tumorigenesis
increases as the number, C, of oncogenic mutations required to
generate a malignant phenotype increases, as judged by a50%
values. When 2 or fewer oncogenic mutations are required, non-
mutator pathways predominate. When 4 or more oncogenic
mutations are required, mutator pathways predominate. When 3
oncogenic mutations are required, the results depend on the
parameter values (Supplementary Table S1 and Figure 2).
Mutation of both copies of a recessive oncogene would count as
2 oncogenic mutations.
When compared to the constant fitness case, incremental
lineage expansion limits the importance of mutator pathways
when two oncogenic mutations are required for cancer (C=2) and
to some extent at C=3 with a low wild type mutation rate (kmut),
but for higher values of C, a50% continues to be well within
commonly observed ranges. For example, when three oncogenic
mutations are required for cancer (C=3), the wild type mutation
rate is low (kmut=10
211), and the relative fitness advantage e
R of
malignant cells relative to wild type is 2, a 770-fold increase in the
mutation rate would be required for mutator pathways to be
observed in 50% of the cancers (Supplementary Table S1). This
increase is at or beyond the upper range of increase in mutation
rate due to common mutator mutations. In contrast, when six
oncogenic mutations are required for cancer (C=6), a50% ranges
from 11–30 (Supplementary Table S1), in the lower range of
commonly observed values of mutation rate increase due to
mutator mutations, suggesting a predominance of mutator
pathways, in that most mutator mutations would then correspond
to a.a50%. Note in Supplementary Table S1 that this result for
C=6 is unchanged for all combinations of wild type mutation
rate, cell generations to cancer, and degree of fitness increase
within the explored parameter values.
When judged by relative efficiency Nrel 1:0, the importance of
mutator pathways is reduced relative to the constant fitness case to
a greater degree than one would judge based on a50%. This is
because the value of Nrel 1:0 is very sensitive to small changes in a,
and therefore a relatively small increase in a is required to
compensate for the effect of incremental lineage expansion on Nrel
1:0. Based on the analytical model, the relative efficiency Nrel 1:0 is
reduced in the case of incremental lineage expansion by a factor of
RT (C21)/[(C+1)C] compared to the constant fitness case.
However, a50% would need to increase by a factor of only {RT
(C21)/[(C+1)C]}
1/C to compensate for this. For example, with
the relative fitness of malignant cells e
R=2, the number of cell
generations T=5000, and the number of required oncogenic
mutations C=6, the relative tumorigenic efficiency Nrel 1:0 is
Figure 2. Log(a50%), for constant fitness and incremental lineage expansion models. The log of a50%, the minimum fold increase in
mutation rate due to a mutator mutation at which mutator pathways contribute to 50% of cancers, plotted as a function of C, the number of
oncogenic mutations required for transformation, for the constant fitness model (red), and the incremental lineage expansion model, with fitness
advantage e
R=1.4 (green) or 2.0 (blue). The fitness advantage due to enhanced proliferation e
RP=1.2 (green) or 1.4 (blue). The black horizontal line
represents a=500. Mutator mutations with a#500 are within the range experimentally demonstrated. All points below the black line represent
scenarios where mutator pathways are favored. Results are shown at T=170 cell generations (A) and at T=5000 cell generations (B). Mutator
pathways are favored in most instances, progressively more so as the number of oncogenic mutations required for malignant transformation
increases. Incremental lineage expansion decreases the degree to which mutator pathways are favored, but only slightly, and this effect progressively
lessens as the number of required oncogenic mutations increases. When 3 oncogenic mutations are required for malignant transformation, mutator
pathways are favored at constant fitness, but not for incremental lineage expansion with a large fitness advantage. Comparing A and B, constant
fitness mutator pathways are more favored with a larger number of cell generations T, whereas this is not the case in the incremental lineage
expansion model. Calculated as in reference [15] for the constant fitness case, and using equations [12a–h] for the incremental lineage expansion
cases, with wild type mutation rate kmut=10
211; and number of loci, mutation of which leads to a mutator mutation, NML=100. These values are
conservative, and higher values would further increase the influence of mutator pathways.
doi:10.1371/journal.pone.0005860.g002
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a 2.7 fold increase in a can restore the same relative importance of
mutator pathways under these circumstances.
The analytical model (equations[11–13] in Methods) shows that
the relative importance of mutator pathways Nrel 1:0 increases with
increasing wild type mutation rate kmut and increasing fold-increase
in mutation rate, a, similar to the constant fitness case [15].
Very large relative fitness advantages for malignant cells e
R
somewhat further reduce the importance of mutator pathways
(Figure 2, Supplementary Tables S1 and S2). For example, when
three oncogenic mutations are required for cancer (C=3), the
number of cell generations to cancer T=5,000, and the wild type
mutation rate is kmut=10
211, a50% is 510 when the relative fitness
advantage e
R of malignant cells relative to wild type is 1.2, 770
when the relative fitness advantage is 2, and 1100 when the
relative advantage is 7.4 (Supplementary Tables S1 and S2).
Finally, the analytical model (equations[11] and [13] in
Methods) shows that the relative importance of mutator pathways
Nrel 1:0 is approximately independent of the number of cell
generations T, in contrast to the constant fitness case, where it is
proportional to T [15]. Different cancer types are thought to
typically arise after different numbers of cell generations T. The
relative importance of mutator pathways in these different cancer
types may thus depend on the fitness landscapes experienced by
cells with less than the full complement of oncogenic mutations.
Case 2: cooperative lineage expansion, early mutator
mutation
In this circumstance, D oncogenic mutations occur leading to a
sudden cooperative increase in fitness. At some time during the
acquisition of these initial D mutations, a somatic mutator
mutation may occur. After the acquisition of the first D oncogenic
mutations, and consequent increase in fitness, an additional C–D
oncogenic mutations must occur to complete the transformation to
a malignant lineage (Figure 1B). a50% is calculated using equation
[16], and Nrel by equation [13], in Methods.
In this case also, mutator mechanisms predominate. The results
with regard to a50% are depicted in Figure 3. As in the incremental
lineage expansion case, the calculations show a slight increase in
a50% relative to the constant fitness case, while still generally
indicating a predominance of mutator pathways. When judged by
relative efficiency Nrel, the importance of mutator pathways is again
reduced relative to the constant fitness case to a greater degree than
one would judge based on a50%, again due to the high sensitivity of
Nrel to the value of a, but a small change in a can compensate.
When compared to the constant fitness case, cooperative lineage
expansion with early mutator mutation limits the importance of
mutator pathways when few oncogenic mutations are required for
cancer (C=2) and to some extent at C=3 with a low wild type
mutation rate (kmut), but for higher values of C, a50% continues to
be well within commonly observed ranges. For example, when
three oncogenic mutations are required for cancer (C=3), the
relative fitness of malignant cells e
R=2, and the wild type
mutation rate is low (kmut=10
211), an 880-fold increase in the
mutation rate would be required for mutator pathways to be
observed in 50% of the cancers (see Figure 3 and Supplementary
Table S1). This increase is at or beyond the upper range of
increase in mutation rate due to common mutator mutations. In
contrast, when six oncogenic mutations are required for cancer
(C=6), a50% ranges from 11–30 (Supplementary Table S1), in the
Figure 3. Log(a50%), constant fitness and cooperative lineage expansion models with early mutator mutation. The log of a50%, the
minimum fold increase in mutation rate due to a mutator mutation at which mutator pathways contribute to 50% of cancers, plotted as a function of C,
thenumberofoncogenicmutationsrequiredfortransformation,forthe constant fitness model(red),andthecooperativelineage expansionmodelwith
earlymutator mutation(CLE-EMM),withfitness advantagee
R=1.4(green)or 2.0 (blue),fitness advantageduetoenhancedproliferation e
RP=1.2(green)
or 1.4 (blue), T=170 cell generations (A) or T=5000 cell generations (B). The black horizontal line represents a=500. Mutator mutations with a#500 are
within the range experimentally demonstrated. Points below the black line represent scenarios where mutator pathways arefavored. Mutator pathways
are generally favored, progressively more so as the number of oncogenic mutations required for malignant transformation increases. CLE-EMM
decreases the degree to which mutator pathways are favored, but only slightly, and this effect progressively lessens as the number of required
oncogenic mutations increases. When 3 oncogenic mutations are required for malignant transformation, mutator pathways are favored at constant
fitness,but notforCLE-EMM anda largefitnessadvantage. ComparingAandB,mutatorpathwaysaremorefavoredwithmorecellgenerations T,for the
constant fitness model, but not for CLE-EMM. Calculated as in reference [15] for the constant fitness case, and using equation [16] for CLE-EMM, with the
number of oncogenic mutations required for cooperative fitness increase D=2 (except for when the number of oncogenic mutations required for
malignant transformation C=2, then D=1); wild type mutation rate kmut=10
211; and number of loci, mutation of which leads to a mutator mutation
NML=100. These values are conservative, and higher values would further increase the influence of mutator pathways.
doi:10.1371/journal.pone.0005860.g003
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increase due to mutator mutations, suggesting a predominance of
mutator pathways.
The analytic models (reference [15] and equations [13–14] and
[16] in this paper) show that mutator pathways are more likely if
they occur early within this window, and also for higher wild type
mutation rate kmut, and fold change a in mutation rate due to a
mutator mutation, similar to the results for the constant fitness and
cooperative lineage expansion with late mutator mutation cases.
Very large relative fitness advantages for malignant cells e
R
somewhat further reduce the importance of mutator pathways
(Figure 3, Supplementary Tables S1 and S2). For example, when
three oncogenic mutations are required for cancer (C=3), the
number of cell generations to cancer T=5,000, and the wild type
mutation rate is kmut=10
211, a50% is 590 when the relative fitness
advantage e
R of malignant cells relative to wild type is 1.2, 880
when the relative fitness advantage is 2, and 1260 when the
relative advantage is 7.4 (Supplementary Tables S1 and S2).
However, in contrast to the constant fitness and cooperative
lineage expansion with late mutator mutation cases, the analytic
model (equations [13] and [16]) shows that the relative
contribution of mutator pathways is independent of number of
cell generations T. Finally, the relative contribution of mutator
pathways is shown by the analytic model (equations [13] and [16])
to be independent of the number of oncogenic mutations required
for an increase in fitness, D, in contrast to the cooperative lineage
expansion with late mutator mutation case.
Case 3: cooperative lineage expansion, late mutator
mutation
In this circumstance, D oncogenic mutations occur leading to a
sudden cooperative increase in fitness. After this occurs, an
additional C–D oncogenic mutations must occur to complete the
transformation to a malignant lineage. During this latter period, a
somatic mutator mutation may occur (Figure 1C). For both
mutator and non-mutator pathways, the lineages will have greater
numbers of cells due to their increased fitness. However, this
increased fitness is constant for both types of pathways, and
remains constant during the period in which the possible
occurrence of a mutator mechanism is being considered. Thus,
the ratio Nrel of malignant cell lineages produced by mutator and
non-mutator pathways will be nearly equivalent to the probability
ratio Prel previously derived for the constant fitness case [15],
except that the parameter C (number of oncogenic mutations
required for cancer) is now replaced by C–D (the number of
oncogenic mutations required for cancer after the original fitness
increase), and a factor representing more rapid acquisition of the
mutator mutation due to more rapid proliferation multiplies Nrel (if
the increased fitness includes more rapid proliferation). a50% is
calculated using equation [20], and Nrel by equation [21], in
Methods.
Mutator mechanisms predominate in most instances as long as
C–D$3 (see Figure 4 and Supplementary Tables S1 and S2), as
judged by the values of a50%. In the case of C–D=3, for example,
a50% ranges from 12 to 252, depending on various parameter
Figure 4. Log(a50%), constant fitness and cooperative lineage expansion models with late mutator mutation. The log of a50%, the
minimum fold increase in mutation rate due to a mutator mutation at which mutator pathways contribute to 50% of cancers, plotted as a function of
C, the number of oncogenic mutations required for transformation, for the constant fitness model (red), and the cooperative lineage expansion
model with late mutator mutation (CLE-LMM), with fitness advantage e
R=1.4 (green) or 2.0 (blue), fitness advantage due to enhanced proliferation
e
RP=1.2 (green) or 1.4 (blue), T=170 cell generations (A) or 5000 cell generations (B). The black horizontal line represents a=500. Mutator mutations
with a#500 are within the range experimentally demonstrated. Points below the black line represent scenarios where mutator pathways are favored.
Mutator pathways are generally favored at constant fitness, progressively with more oncogenic mutations required for malignant transformation.
CLE-LMM decreases the degree to which mutator pathways are favored, but this effect lessens with more required oncogenic mutations. When 3–4
oncogenic mutations are required for malignant transformation, mutator pathways are favored at constant fitness, but not for CLE-LMM. In contrast
to other cases (Figures 2–3), a larger fitness advantage has a small effect in increasing the influence of late mutator pathways. Mutator pathways are
increasingly favored with more cell generations T for all models. Calculated as in reference [15] for the constant fitness case, and using equation [20]
for the cooperative lineage expansion cases, with the number of oncogenic mutations required for cooperative fitness increase D=2 (except for
when the number of oncogenic mutations required for malignant transformation C=2, then D=1); wild type mutation rate kmut=10
211; and number
of loci, mutation of which leads to a mutator mutation NML=100. These values are conservative, and higher values would further increase the
influence of mutator pathways.
doi:10.1371/journal.pone.0005860.g004
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within that seen with known mutator mutations. As the number of
oncogenic mutations required for cancer after the original fitness
increase (C–D) increases further, greater predominance of mutator
pathways is expected. For cooperative lineage expansion with C–
D,3, non-mutator pathways, or mutator pathways with early
mutator mutations, are more likely pathogenic mechanisms.
Importantly, the analytic results (equations [20–21] in Methods)
imply that the importance of this pathway may depend on the
number of oncogenic mutations required for increased fitness, D,
when other parameters, including the number of oncogenic
mutations to cancer C, are held constant. In this case, the fewer
oncogenic mutations are required for increased fitness, the greater
the relative predominance of this mutator pathway with late
mutator mutations. The dependence of the results on D is
illustrated in Figure 5 and documented for other parameter values
in Supplementary Table S2. As in the constant fitness case,
mutator pathways are also more likely if they occur early within
this window, and for higher wild type mutation rate kmut, fold
increase a in mutation rate due to a mutator mutation, and
number of cell generations T.
For the cooperative lineage expansion case with late mutator
mutation, the relative importance of mutator pathways is
somewhat further increased at very large relative fitness advantages
for malignant cells, e
R (Figure 4, Supplementary Table S2), in
contrast to the incremental lineage expansion case (case 1) and the
cooperative lineage expansion case with early mutator mutation
(case 2). In the cooperative lineage expansion case with late
mutator mutation, a greater fitness advantage increases the pool of
cells which may acquire a late mutator mutation. For example,
when the number of oncogenic mutations required for cancer
C=6, the number of oncogenic mutations required for the
cooperative fitness increase D=2, the number of cell generations
to cancer T=5,000. and the wild type mutation rate kmut=10
211,
a50% is 29 when the relative fitness advantage e
R of malignant cells
relative to wild type is 1.2, 27 when the relative fitness advantage is
2, and 22 when the relative advantage is 7.4 (Supplementary
Tables S1 and S2).
Case 4: negative clonal selection
In this model, lineages have a constant risk per cell per cell
generation of suffering a reduction in their fitness. Lineages with
fitness reduction are assumed to eventually become extinct (the
probability of this occurring is very high in large cell populations
[17]). This phenomenon was previously studied in isolation, and
termed negative clonal selection (NCS) [17]. In the current model,
those lineages which do not become extinct are at the same time
continuously and progressively acquiring oncogenic mutations.
The instantaneous risk of fitness reduction is the product of the
mutation rate per nucleotide base per cell generation kmut (or
akmut after a mutator mutation) and NRFLN-D (Nreduced fitness loci net-
dominant), an indicator of the vulnerability of the genome to
Figure 5. Cooperative lineage expansion: late mutator pathways less favored with increasing mutations required for fitness
increase. The log of a50%, the minimum fold increase in mutation rate due to a mutator mutation at which mutator pathways contribute to 50% of
cancers, plotted for the number of oncogenic mutations required for malignant transformation C=6, as a function of the number of oncogenic
mutations required for the cooperative fitness increase, for wild type mutation rate kmut=10
211 (red, green) or 10
29 (blue, purple), number of cell
generations T=170 (red, blue) or 5000 (green, purple), and a large fitness advantage e
R=7.4 and fitness advantage due to enhanced proliferation
e
RP=3.7. The black horizontal line represents a=500. Mutator mutations with a#500 are within the range experimentally demonstrated. All points
below the black line represent scenarios where mutator pathways are favored. Mutator pathways are generally favored, but late mutators (occurring
after the fitness increase) are less favored the more oncogenic mutations are required for the fitness increase. Late mutator pathways are more
favored in the cooperative lineage expansion case for higher wild type mutation rates kmut and more cell generations to cancer T. Calculated using
equation [20], with the number of loci, mutation of which leads to a mutator mutation, NML=100. This value is conservative, and a higher value
would further increase the influence of mutator pathways.
doi:10.1371/journal.pone.0005860.g005
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single copy mutation of which may reduce fitness of the lineage,
where the loci are divided into subclasses, and the number in each
subclass is multiplied by the probability that a mutation of it will
lead to a fitness reduction as a function of genetic and
environmental context. As in the constant fitness case [15], and
the incremental lineage expansion case (case 1 above), we
approximate mutator pathways by considering mutator mutations
occurring as an initial step in tumorigenesis. Nrel (which in this
case is equal to the relative probability Prel of mutator versus non-
mutator pathways) is calculated using equations [28–30] in
Methods.
In contrast to the other cases, the relative efficiency Nrel of
mutator to non-mutator pathways does not continue to increase
with greater fold increases a in the mutation rate. Increased
mutation rates speed the acquisition of oncogenic mutations, but
at the same time increase the risk of fitness reduction and
extinction. In this type of fitness landscape, the relative efficiency
Nrel of mutator compared to non-mutator pathways increases with
greater fold increases a in mutation rate, until an optimum at
which the growth of the malignant lineage begins to be limited by
negative clonal selection. An approximate optimum for mutation
rate kmut can be estimated for this circumstance from the
theoretical treatment:
kmutoptimal~
C
2NRFLN{DT
: ð1Þ
Note that the treatment focuses on dominant reduced fitness
mutations only. Recessive reduced fitness mutations, requiring
mutation of both alleles, were found to be quantitatively
insignificant [17].
Within the parameter ranges considered within this paper, the
optimal mutation rate for tumor evolution, kmut optimal, varies from
2.1610
210 to 3.6610
26 per nucleotide base per cell generation.
This optimum is generally higher than estimated mutation rates of
wild type embryonic stem cells or somatic cells [23–24], 10
211 to
10
29.
An approximately optimal value of the fold increase a in
mutation rate due to a mutator mutation is therefore given by
aoptimal=k mut optimal/kmut. In the presence of an anti-apoptotic
mutation [25], the vulnerability of the genome NRFLN-D would be
reduced to a very low value, further raising the optimal mutation
rate and diminishing the potential effect of negative clonal
selection. Thus, mutator pathways with a.aoptimal would be
more efficient if they occurred after an anti-apoptotic mutation.
The relative importance of mutator pathways increases with
increasing number of required oncogenic mutations for malignant
transformation, but in contrast to the other cases, the minimal
number of oncogenic mutations at which mutator pathways are
favored [log (Nrel 1:0).0] varies depending on the strength of
negative clonal selection, as shown in Figure 6 for a fold increase in
mutation rate a=100, a wild type mutation rate kmut=10
211, and
a number of cell generations to cancer T=5,000. At maximal
negative clonal selection, there must be at least 5 oncogenic
mutations required for malignant transformation before mutator
pathways are favored. Additional more detailed results are given in
Supplementary Table S3. In general mutator pathways are
favored when 5 or more oncogenic mutations are required for
malignant transformation and not favored when 2 or fewer
oncogenic mutations are required. Results when 3 or 4 oncogenic
mutations are required depend on parameter values.
Whereas in the absence of negative clonal selection, higher
values of the fold increase a in mutation rate due to a mutator
mutation, number of cell generations T, and wild type mutation
rate kmut generally favor mutator mutations, in the presence of
negative clonal selection the relative importance of mutator
pathways depends on the parameter values in a complex way.
Figure 7 depicts the relative prevalence of mutator pathways with
initial mutator mutations Nrel 1:0 as a function of a, for the highest
levels of negative clonal selection, with the number of oncogenic
mutations required for cancer C=5, the number of cell
generations to cancer T=5,000, and the wild type mutation rate
kmut=10
211, illustrating the decrease in the relative importance of
mutator pathways beyond an optimum. Supplementary Table S3
shows the relative probability of a mutator pathway with an initial
mutator mutation compared to no mutator pathway, in the
presence of negative clonal selection (Nrel 1:0, NCS) for numerous
combinations of parameter values not shown in the Figures.
Figure 6. Relative efficiency of mutator compared to non-
mutator pathways in the presence of negative clonal selection.
The logarithm of Nrel (equal to the logarithm of Prel), the relative
prevalence or efficiency of mutator pathways compared to non-mutator
pathways, is plotted as a function of the number of oncogenic
mutations required for malignant transformation, for varying values of
negative clonal selection. Mutator pathways lead to 50% of clinical
cancers when log (Nrel)=0 (pink line), and are favored for all positive
values of log (Nrel) (above pink line). The negative clonal selection
parameter NRFLN-D (Nreduced fitness loci net-dominant) is an indicator of the
vulnerability of the genome to mutations which may reduce cellular
fitness [17]. It consists of the number of loci, in base pairs, single copy
mutation of which may reduce fitness of the lineage, where the loci are
divided into subclasses, and the number in each subclass is multiplied
by the probability that a mutation of it will lead to a fitness reduction as
a function of genetic and environmental context. It is varied from 0 (no
negativeclonalselection,constantfitness,red),tointermediate(NRFLN-D=
9.8610
4, green) to high (NRFLN-D=9.8 610
5, blue). Low negative clonal
selection (NRFLN-D=9.8610
3) is not shown, as it is superimposable on no
negative clonal selection for the plotted parameter values. Whereas
mutator pathways are favored for 3 or more oncogenic mutations
required for transformation at no or intermediate negative clonal
selection, under strong negative clonal selection 5 or more oncogenic
mutations must be required for transformation before mutator pathways
are favored. Calculated using equations [28–30], with the wild type
mutation rate kmut=10
211, the fold increase in mutation rate due to a
mutator mutation a=100, the number of cell generations T=5000, and
the number of loci, mutation of which leads to a mutator mutation,
NML=100.
doi:10.1371/journal.pone.0005860.g006
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This paper highlights a new approach to evaluation of the
importance of somatic mutator mutations in tumorigenesis. The
relative efficiencies of mutator and non-mutator pathways are
considered, thus circumventing the need for comparisons of
absolute rates of tumorigenesis with epidemiologic data, with their
inherent limitations such as the assumption that every malignant
cell becomes a clinical cancer. It was previously shown that
mutator pathways are generally more efficient in the setting of
constant fitness despite requiring an additional step for acquisition
of the mutator mutation [15]. More efficient mechanisms are likely
to play a proportionately larger role in tumorigenesis.
However, tumorigenesis involves changes in fitness including
decreased fitness leading to extinction (negative clonal selection)
and increased fitness leading to lineage selection and expansion.
These could have profound effects on the relative importance of
mutator pathways in tumorigenesis. Hence, in the present work I
quantitatively consider the variations in fitness that have
historically been raised as counterarguments to the mutator
hypothesis. This analysis confirms the importance of mutator
pathways in tumorigenesis across most representative fitness
landscapes. Importantly, the results do not negate the important
role for simultaneous lineage expansion and selection.
In all cases, mutator pathways are favored when there are more
oncogenic mutations required for cancer. Depending on the
situation, mutator pathways will be favored when the number of
required oncogenic mutations exceeds the range of 3–5. Genome
wide sequencing of solid tumors suggests tumors may harbor
between 14–20 oncogenic mutations [26–27].
The functional dependence of the importance of mutators on
other key parameters varies depending on the different cases
considered. For example, in some cases, increasing the number of
cell generations T enhances the importance of mutators, in others
it has no effect, and in still others there is an optimum beyond
which further increases in T decrease the importance of mutators.
The case which best matches clinical phenomena needs to be
determined and may vary for different cancer types. For constant
fitness models, negative clonal selection models, and incremental
lineage expansion models, mutator mutations are more efficient if
they occur early. However, for cooperative lineage expansion
models, whether it is more efficient for the mutator mutations to
occur before (case 2) or after (case 3) lineage expansion onset
depends on the parameters, and can be determined in any
particular circumstance by comparing Nrel, the relative efficiency
of mutator compared to non-mutator pathways, for case 2 and
case 3.
While the models generally predict that mutator mutations are
an early event, this may be difficult to verify experimentally.
Mutator mutations may occur in only a minority of premalignant
lesions, but the mutator premalignant lesions are predicted to
overwhelmingly be the ones that actually develop into cancers.
The model allows the calculation of the fraction of pre-malignant
lesions with a given number of oncogenic mutations that harbor
mutator mutations in exactly the same way that it allows
calculation of the fraction of malignant tumors which develop by
the mutator pathway as a function of the number of oncogenic
mutations. It therefore follows that premalignant lesions with two
or less oncogenic mutations will be less likely to harbor a mutator
mutation, but that those few mutator early premalignant lesions
will ultimately produce the majority of advanced premalignant
lesions and cancers. Since the mutator lesions become progres-
sively enriched with increasing progress towards malignancy, any
experimental technique which looks at average mutation frequen-
cy across many premalignant lesions might falsely conclude that a
mutator mutation is a ‘‘late event’’. One would need to be able to
look at the presence or absence of a mutator mutation in large
numbers of premalignant lesions and/or cells individually to verify
this prediction. The mutator lesions and/or cells may remain in
the minority until lesions with 3–4 or more oncogenic mutations
are surveyed.
The analysis predicts that for genetic DNA repair syndromes
such as xeroderma pigmentosum (XP) and hereditary non-
polyposis colon cancer (HNPCC), simple relationships will obtain
between the observed degree of increased risk, the number of
oncogenic mutations required for malignant transformation, the
time to cancer onset, and the increased mutation rate as a result of
the disorder. These parameters are all measurable, with the
exception of the number of oncogenic mutations required for
malignant transformation, which can be estimated based on
evolving molecular knowledge in experimental systems.
The model also predicts that in syndromes with inherited
mutator mutations such as HNPCC, premalignant lesions such as
polyps will be more efficiently converted to cancer. Because of this
very efficient acquisition of additional oncogenic mutations,
HNPCC can result in a higher number of cancers without a
higher number of polyps. The greater enhancement of number of
cancers compared to the enhancement of the number of polyps
can be anticipated based on the greater number of oncogenic
mutations required to produce the former. In contrast, in a genetic
cancer syndrome which is not based on a mutator mutation,
familial adenomatous polyposis (FAP), we see an increase in the
number of polyps at least equivalent to the increase in the number
of cancers.
Figure 7. Relative efficiency of mutator pathways with
negative clonal selection versus magnitude of mutation rate
increase. The relative efficiency of mutator compared to non-mutator
pathways Nrel is plotted against the logarithm of the fold-increase in
mutation rate due to a mutator mutation a, for three a values (20, 100,
1000) at high negative clonal selection (net number of dominant
reduced fitness loci NRFLN-D=9.8610
5). In contrast to all models without
negative clonal selection, a 100-fold increase in the mutation rate leads
to a more efficient mutator pathway than a 1,000-fold increase.
Calculated using equations [28–30], with the number of oncogenic
mutations required for malignant transformation C=5; number of cell
generations to cancer T=5000; wild type mutation rate kmut=10
211;
number of loci, mutation of which leads to a mutator mutation,
NML=100.
doi:10.1371/journal.pone.0005860.g007
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accessible through HNPCC will result in an increased risk of colon
cancer but not of embryonal carcinomas. Thus, in HNPCC, in
which a single further mutation confers a mutator phenotype,
there is no increased risk of embryonal cancers, which require
fewer oncogenic mutations in their formation, despite an increased
colon cancer risk corresponding to the larger number of oncogenic
mutations in the pathogenesis of colon cancer. In retinoblastoma,
few oncogenic mutations are required, but as the mutator
mutation is also the pathognomonic oncogenic mutation, its
occurrence is favored.
In the case of negative clonal selection, tumorigenic efficiency
does not continue to increase with increased mutation rate, and
actually decreases beyond an optimum rate. The optimal mutation
rate for tumor evolution is consistently higher than one published
estimate of the mutation rate of embryonic stem cells [23], and is
generally higher than the estimates for mutation rates of somatic
cells [24]. If we assume the estimate of the stem cell mutation rate
is correct, and that it has evolved to be optimal for species
evolution, the comparison emphasizes that while tumor and
species evolution may be partially analogous, they may differ in
important quantitative and even qualitative features. Thus,
mutator mutations may be important for the evolution of tumors
without being important in species evolution.
The optimum mutation rate for tumor evolution estimated by
this treatment is analogous to the optimum mutation rate for
viruses under selection pressure from antiviral therapy [28–29],
which is the reciprocal of the viral genome length. The present
work differs in that it assumes multiple steps are required for
malignant transformation (hence the factor C), that not all sites
when mutated lead to reduced cellular fitness (hence NRFLN-D
rather than the full genome length), that either member of a
diploid gene pair can suffer a reduced fitness mutation (hence the
factor of 2), and that multiple cell generations, rather than 1, need
to be considered (hence the factor T).
The increased optimal mutation rate calculated here for tumors
is consistent with the several experimental demonstrations of
increased tumor incidence in mice genetically engineered to have
mutator mutations [30–32], as well as the several hundred fold
higher random mutation frequency in human tumors observed
experimentally compared to surrounding normal tissues, when
mutations are measured at a genetically neutral site [20]. Note
these mutations in human tumors may be present in only a very
small minority of cells within a tumor mass, and can be detected
only by PCR amplification from single copies [20]. While the
observed random mutation frequency also depends on the number
of cell generations, it is unlikely the cell generation number
increase in tumors is several hundred fold relative to normal
tissues. In colon cancer for example, the normal tissue arises from
a highly proliferative stem cell compartment which has been
proliferating since birth. Finally, the derivation of an optimal
mutation rate greater than wild type is consistent with studies of
bacteria competing for survival in culture, which show the winners
have an increased, but not excessively increased, mutation
frequency [Loh E, Salk JS, Loeb LA, unpublished].
I will now briefly consider the more speculative questions raised
in the introduction.
1. As mutator pathways appear to predominate in most instances,
can the diversity and complexity of tumors be addressed by
current therapeutic strategies?
Clinically, mutator lineages will lead to enhanced heterogeneity
within tumors, enhancing the probability that a sub-population of
tumor cells manifests pre-existing resistance to therapy. In
addition, sensitive cells within mutator lineages will evolve to
resistance more quickly. Both pre-existing and acquired resistance
emphasize the need for therapeutic combinations [22].
2. Can tumor diversity and genetic instability be used to stratify
patients for prognosis and therapy?
The question of how many agents to give in combination,
especially when limited by toxicity, may depend on measures of
underlying tumor diversity and plasticity.
3. Can therapy be designed to increase the mutation rate in
tumors beyond the optimum derived in this paper, resulting in
lethal mutagenesis?
The proposed anti-cancer strategy termed ‘‘lethal mutagenesis’’
[33] involves increasing the mutation rate to the point where
negative clonal selection threatens survival of the malignant
lineage. The mathematical model of negative clonal selection can
potentially be adapted to allow estimation of the tumor mutation
rates which need to be reached to achieve this effect, as well as the
mutational ‘‘therapeutic window’’ between tumor and normal
tissue. Current inhibitors of cell cycle checkpoint kinases, under
preclinical and clinical development as chemotherapy and
radiation sensitizers, exemplify methods to further enhance the
mutagenic effect of therapy, by bypassing pauses for repair of
DNA damage [34]. These agents may be selective based on the
absence of a functional p53 checkpoint in tumors.
4. Can the onset of tumors be delayed to beyond the human
lifetime, and therefore prevented, by small decreases in the
mutation rate?
As cancer is generally a disease of the elderly, only a modest delay
in its onset is required to reduce its importance compared to other
causes of mortality. As the efficiency of tumorigenesis is a function
of the mutation rate raised to the power of the number of
oncogenic mutations required for malignant transformation, only
a very modest reduction in mutation rate would be required to
delay the onset of cancer [35]. This in turn suggests that
prevention of cancer through public health and/or pharmacologic
measures aimed at reducing the mutation rate could be effective.
5. What are the underlying reasons for quantitative differences
between tumor and species evolution?
The genome may be more tolerant of mutation in the context of
tumorigenesis, in which homeostasis need not be maintained in the
whole organism, than in the evolution of species, in which this
homeostatic constraint must be obeyed. This may result in a
higher optimum mutation rate for tumor evolution.
Insummary,thispaperprovidesageneralquantitativeevaluation
of the relative importance of mutator pathways compared to non-
mutator pathways in tumorigenesis, accounting for fitness variation
and selection, thus directly addressing the major historical criticisms
of the mutator hypothesis. Mutator pathways predominate in most
but not all instances. The optimal mutation rate is higher for tumor
evolution than for species evolution.
Methods
The present work builds on methods previously published
concerning both tumor evolution at constant fitness [15] and
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However, it significantly extends this work by providing a general
analytic solution for determining the relative efficiency of mutator
pathways, compared to non-mutator pathways, for fitness
pathways involving increased fitness of malignant lineages and
their precursors, as well as providing an analysis of negative clonal
selection in the presence of tumor evolution.
All the models are ‘‘multi-hit models’’, in that malignant
lineages, with C oncogenic mutations, arise by mutation from
precursor lineages with C21 mutations, which in turn arise from
precursor lineages with C22 mutations, etc. In the constant fitness
case, the probability of having C oncogenic mutations at time T is
derived for the non-mutator pathway based on minimal
assumptions. The corresponding quantity for the mutator pathway
is then the probability weighted integral of all the possible
pathways with an additional somatic mutator mutation occurring
at any time between 0 and T [15].
In the original negative clonal selection work, the number of
viable lineages surviving decays exponentially with a time constant
b equal to the product of the mutation rate per base per cell
generation, kmut, and a general indicator of the vulnerability of
cellular fitness to dominant mutation, NRFLN-D, the net number of
loci in bases, single copy mutation of which will reduce fitness,
adjusted for the probability of fitness reduction associated with
each locus, summed over possible genetic and environmental
contexts. The asssumption that all lineages with reduced fitness
will become extinct is nearly true for large populations, and
dominant reduced fitness mutations are of greater quantitative
significance than recessive ones [17].
The models do not assume that different lineages are competing
for an ecologic niche of a fixed size, as is often the case in
evolutionary game theory and related techniques [36]. It is
assumed that wild type lineages maintain their numbers and the
size of their ecological niche, lineages with reduced fitness become
extinct, and lineages with increased fitness, including malignant
lineages and their precursors, increase exponentially at rates
determined by their relative fitness, potentially breaking anatomic
barriers to form malignant or benign tumors respectively within
expanded niches. These assumptions, intuitively aligned with the
occurrence of benign premalignant lesions in solid tumors, enable
the derivation of complete analytic solutions incorporating both
multi-hit tumorigenesis and arbitrarily varied fitness landscapes.
The exponential growth rates are determined by relative fitness
R. This follows from the assumption that the change in relative
numbers of a lineage per unit time is proportional to its relative
fitness, i.e.:
dN
N
~R dt, ð2Þ
where N is the number of cells, dN/N is the change in their
relative number, R is the relative fitness, and dt is an instant of
time measured in cell generations. Integrating [2] from 0 to T cell
generations leads to an exponential growth equation depending on
relative fitness, i.e.
N!eRT: ð3Þ
Exponential growth is thought to characterize nascent tumors
until they reach a limiting size [37]. Note a relative fitness of zero
corresponds to wild type fitness and results in constant numbers
over time.
The lineage expansion models (cases 1–3) are formulated in
terms of ‘‘expectation values,’’ or the mean number of malignant
cell lineages generated by a particular tumorigenic mechanism at a
reference timepoint. This is in contrast to the constant fitness
model in which a single cell lineage experiences a limited number
of cell divisions, so that mutation in any single nucleotide locus
during the lifetime of a single cell and its progeny is a rare event.
Probabilities of rare events joined as ‘‘or’’ approximately add (P(A
or B)<P(A)+P(B)), and the constant fitness model is expressed in
terms of probabilities [15]. In the presence of lineage expansion, a
large population of N cells may result from the lineage of a single
cell, where N is equal to or greater than the reciprocal of the per
nucleotide mutation rate per cell generation times the number of
cell generations [38]. In that instance, the probability that at least
one cell in this population harbors a mutation at a particular
nucleotide locus may approach 1, and probabilities of individual
events joined as ‘‘or’’ do not simply add. However, expectation
values are still additive under an ‘‘or’’ operation, simplifying the
theoretical treatment. Biologically, this corresponds to the
postulate that not every malignant lineage leads to a clinical
cancer, and the mechanisms which produce the most malignant
lineages are most likely to contribute to tumorigenesis.
The models are designed for large cell populations. In scenarios
where there are small clusters of cells, such as intestinal crypts, the
models may be thought of as reflecting the average behavior of a
population of crypts, including the fact that benign tumors or
polyps may arise in some.
Other key assumptions, parameters, and parameter values have
been previously reviewed [15,17]. Key input and output
parameters and their values are also given in the ‘‘Results’’ section
and in Table 1.
Below we give the equations used to calculate the results in this
paper and the general strategy for deriving them. Full derivations
are available upon request. These full derivations also include
demonstrations that all cases are identical to the previously derived
constant fitness case [15] in the limit where the natural log fitness
advantage R (cases 1–3) or susceptibility constant b for negative
clonal selection (case 4) approach 0, serving as a check on the
mathematics.
Case 1: Incremental Lineage Expansion
Given the assumption that any fully malignant lineage with C
oncogenic mutations has an equal chance of becoming a clinical
cancer, Nrel, the relative number of clinical cancers due to mutator
compared to non-mutator pathways at time T or earlier, is given
by:
Nrel~NCi,C{mut T ðÞ =NCi,C T ðÞ , ð4Þ
where NCi,C-mut(T) and NCi,C(T) are the number of new lineages
initiated with C oncogenic mutations, and C oncogenic mutations
are required for malignant transformation, up to and including
time T, for mutator and non-mutator pathways, respectively.
The model is a multi-hit model wherein C oncogenic mutations
are required for tumorigenesis, and is described by a network of
ordinary differential and integral equations. Lineages with no
oncogenic mutations do not increase their numbers (denoted N0),
but lineages with n oncogenic mutations increase in number by a
factor of e
nR/C each wild type cell generation. Hyperproliferative
mutations which decrease the generation time are appropriately
factored into the value of R.
Lineages with n mutations also increase their numbers by
initiation events: i.e., mutations from the lineages with n21
oncogenic mutations. The rate of initiation of new lineages with n
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product of the number of cells with n21 oncogenic mutations at
that instant, Nn21,C (t); the mutation rate, kmut; the number of
remaining unmutated oncogene loci, NOL-n+1 (where NOL is the
number of oncogenic loci available for mutation in a wild type
cell); and a factor to account for more cell generations per unit
time if there is a hyper-proliferative mutation, e
Rp:
dNni,C t ðÞ ~Nn 1,C t ðÞ kmut NOL{nz1 ½  eRpdt: ð5Þ
The negligible effect of mutation in decreasing precursor
populations is ignored, simplifying the treatment. The total
number of lineages with n mutations initiated by time T is the
integral of the instantaneous initiation rate from 0 to T:
Nni,C T ðÞ ~
ð T
0
dNni,C t ðÞ : ð6Þ
The number of cells in a given class of lineage by time T is given
by the integral of the instantaneous initiation rate at time t,
multiplied by the lineage expansion from time t to T for that
lineage class, over the interval t=[0,T].
Nn,C T ðÞ ~
ð T
0
e
nR T{t ðÞ
C dNni,C t ðÞ : ð7Þ
In particular, malignant initiation events occur from lineages
with C21 oncogenic mutations, as they acquire their Cth
oncogenic mutation:
dNCi,C t ðÞ ~NC{1,C t ðÞ kmut NOL{Cz1 ½  eRpdt: ð8Þ
The total number of malignant initiation events by time T is
simply the integral of this instantaneous initiation rate from 0 to T:
NCi,C T ðÞ ~
ð T
0
dNCi,C t ðÞ : ð9Þ
In summary, the instantaneous initiation rate of lineages with one
oncogenic mutation is given by a first order differential equation.
Based on the instantaneous initiation rate of lineages with one
oncogenic mutation, and their lineage expansion, one can derive an
expression for the number of cells with one oncogenic mutation as a
functionoftime.Theinstantaneousrateofinitiationoflineageswith
two oncogenic mutations is proportional to the number of cells with
one oncogenic mutation at any given time. In turn, based on the
instantaneous initiation rate of lineages with two oncogenic
mutations, and their lineage expansion, we derive an expression
for the number of cells with two oncogenic mutationsat any point in
time. The instantaneous initiation rate of cells with 3 oncogenic
mutations is then proportional to the number of cells with 2
oncogenic mutations, and so on.
Expressions for the number of cells and lineage initiations were
derived for several values of n (number of oncogenic mutations)
and C (number of oncogenic mutations required for malignant
transformation), and based on the algebraic details, general
expressions were hypothesized for all n and C, verified for the
cases explicitly derived, and proven for all n and C by
mathematical induction.
For mutator pathways, the mutator mutation is assumed to
occur first, based on previous work suggesting that mutator
pathways are more efficient if the mutator mutation occurs early
[15]. The rate of formation of cells with the original mutator
mutation, dN0,C-mut (t), is given by the product of the initial
number of cells N0, the number of mutator loci NML, and the
mutation rate:
dN0,C-mut t ðÞ ~N0 NML kmut dt: ð10Þ
Once a lineage with a mutator mutation is formed, analysis of its
progress parallels that of the non-mutator pathway, except for the
increase in the mutation rate constant by the factor a.
The numbers of malignant cell initiations by both mutator and
non-mutator pathways is the sum of exponentials representing
lineages with 0 to C21 oncogenic mutations. a50%, the minimum
foldincreaseinmutationrateatwhichmutatorpathwaysaccountfor
50% of observed cancers (derived by setting Nrel=1), is approxi-
mated by considering only the most rapidly growing exponential:
a50%~
C{1 ðÞ R
NMLkmutC
   1
C
: ð11Þ
The exact expression, considering all exponentials, is:
a50%~
A
B
   1
C
; ð12aÞ
A~
1
C{1 ðÞ !
Ckmut
R
   C X C{1
a~1
Ga e
aRT
C {1
  
z{ 1 ðÞ
C{1RT
C
"#
;ð12bÞ
Ga,a=0~
{1 ðÞ
C{a
a
C{1
a
  
, ð12cÞ
where
C{1
a
  
~
C{1 ðÞ !
a! C{1{a ðÞ !
, ð12dÞ
the number of combinations, or ways ‘‘a’’ oncogenes can be
selected from a set of C21 oncogenes, without regard to the order
of selection;
B~NML
Ckmut
R
   Cz1
X C{1
a~1
Ga,mut e
aRT
C {1
  
zb0,C
RT
C
z
bT,C
2
RT
C
   2 "#
;
ð12eÞ
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{1 ðÞ
C{1{a
a2 a ðÞ ! C{1{a ðÞ !
; ð12fÞ
b0,C~{
X C{1
a~1
{1 ðÞ
C{1{a
aa ðÞ ! C{1{a ðÞ !
; ð12gÞ
bT,C~
{1 ðÞ
C{1
C{1 ðÞ !
: ð12hÞ
A and B are proportional to the number of initiation events by
time T for non-mutator and mutator pathways (with a=1),
respectively. The approximate expression [11] is within 1% of the
exact expressions [12a–h] for the vast majority of cases, and within
5% for all cases examined.
Nrel, the relative efficiency of mutator compared to non-mutator
pathways, is given by the following expression when the mutator
mutations increase the mutation rate by a factor of a:
Nrel~
aC
aC
50%
: ð13Þ
Case 2: Cooperative Lineage Expansion, Early Mutator
Mutation
In this case, there is no change in fitness until D#C oncogenic
mutations have occurred. These first D steps, with or without a
mutator mutation, can therefore be analyzed using the strategy
previously outlined for the constant fitness case [15]. In this case,
for the mutator pathway, the mutator mutation is allowed to occur
anywhere up to (but not including) the point where D oncogenic
mutations have occurred, and these D possible time intervals are
summed.
Once D oncogenic mutations have occurred, the lineage has a
natural log fitness advantage R, and expands by a factor of e
R per
wild type cell generation (see equations [2–3] above). During this
period, the fitness is also constant, although greater than it was
prior to the D oncogenic mutations. The total number of cells with
C21 oncogenic mutations (by non-mutator or mutator pathways)
at time T is given by the integral over t from 0 to T of the product
of: the number of cells ND21,C (t) or ND21,C-mut (t) with D21
oncogenic mutations (without or with a mutator mutation,
respectively) at time t; the instantaneous mutation rate per locus
for conversion to cells with D oncogenic mutations (kmut for non-
mutators, a kmut for mutators); the number of unmutated
oncogenic loci at the time of conversion to cells with D oncogenic
loci (NOL2D+1), the exponential lineage expansion of cells with D
oncogenic mutations from time t to time T (e
R(T-t)); and the
probability that any progeny of this expanded lineage would have
acquired the final C2D21 oncogenic mutations in time T2t
(PC21|D,C(T2t) or PC-1|D,C-mut(T2t)) for non-mutators and
mutators, respectively, adjusted for the absence or presence of
mutator mutations and the increased number of cell generations
per unit time, if the fitness increase includes an increase in
proliferation rate:
NC{1,C T ðÞ ~
ð T
0
ND{1,C t ðÞNOL{Dz1 ðÞ kmuteRT {t ðÞ PC{1D j ,C T-t ðÞ dt,
ð14aÞ
NC{1,C{mut(T)~
ð T
0
ND{1,C{mut t ðÞNOL{Dz1 ðÞ akmuteRT {t ðÞ PC{1 D,C{mut j T-t ðÞ dt:
ð14bÞ
The probability of the expanded lineage acquiring C2D21
oncogenic mutations in time T-t is the product of the number of
ways of selecting C2D21 oncogenic mutations from NOL-D
remaining unmutated oncogenic loci,
NOL{D
C{D{1
  
; and the
single step mutation probability per locus (kmut(T2t) for non-
mutators, a kmut(T2t) for mutators, adjusted by a factor of eRp to
account for increased number of cell generations per unit time if
there is a hyperproliferative mutation), raised to the (C2D21)st
power:
PC-1jD,C(T{t)~
NOL{D
C{D{1
  
eRppkmut T{t ðÞ
   C{D{1
, ð15aÞ
PC{1D , C {mut j T{t ðÞ ~
NOL{D
C{D{1
 !
eRpakmut T{t ðÞ
   C{D{1
:
ð15bÞ
As in case 1, we use the number of cells with C21 oncogenic
mutations to calculate the instantaneous rate of malignant
initiation events at any time, integrating that from 0 to T to
obtain the number of malignant initiation events at or prior to T.
Nrel, the relative number of clinical cancers due to mutator
compared to non-mutator pathways at time T or earlier, is given
as before by the ratio of total number of malignant initiation
events at or before time T for mutator divided by non-mutator
pathways (see equation [4]). a50% is again derived by setting
Nrel=1.
An approximate expression for a50%, in the limit of significant
lineage expansion, and increasingly accurate as the fitness
advantage R and the fold mutation rate increase a get larger, is:
a50%~
R
NMLkmut
   1
C
: ð16Þ
Nrel is again given by [13].
Case 3: Cooperative Lineage Expansion, Late Mutator
Mutation
In this case, there is no change in fitness and no mutator
mutation until D#C oncogenic mutations have occurred. These
first D steps can therefore be analyzed using the strategy previously
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[15].
Once D oncogenic mutations have occurred, the lineage has a
natural log fitness advantage R, and expands by a factor of e
R per
wild type cell generation. During this time, an additional C2D
oncogenic mutations will also occur, with a mutator mutation
occurring anywhere from the 1
st to (C2D)th step in the process.
During this period, the fitness is also constant, although greater
than it was prior to the D oncogenic mutations.
The total number of cells with C21 oncogenic mutations at
time T by a mutator mechanism, NC21,C-mut(T), is given by the
sum, over the possible steps k at which a mutator mutation can
occur, of double integrals. These double integrals from t equals 0
to T are of the product of the number of cells with D21 oncogenic
mutations at time t, ND21,C-mut(t); the instantaneous rate of
conversion of these cells to cells with D oncogenic mutations,
(NOL2D+1) kmutdt; the lineage expansion from time t to T,
e
R(T2t); and an internal integral representing the likelihood of
subsequent acquisition of the remaining C2D21 oncogenic
mutations and a mutator mutation in time T-t. This internal
integral is over t’ equals 0 to T-t, and the integrand is the product
of the probability of having k21 additional oncogenic mutations
between time t and time t+t’ before the mutator mutation occurs,
Pk21,t’; the instantaneous rate of occurrence of the mutator
mutation (adjusted to account for the reduced cell generation time
in the presence of a hyperproliferative mutation) at time t’, e
Rp
NML kmut dt’; and the probability that the remaining C2D2k
oncogenic mutations will occur in the remaining T2t2t’ cell
generations, PC21,k21,t’,t.
NC{1,C{mut T ðÞ ~
X C{D
K~1
ð T
t~0
ð T{t
t’~0
ND{1,C{mut t ðÞNOL{Dz1 ðÞ kmuteRT {t ðÞ Pk{1,t’eRpNMLkmutPC{1,k{1,t’,tdt’dt:
ð17Þ
In analogy with previous arguments,
Pk{1,t’~
NOL{D
k{1
  
eRpkmutt’
   k{1
, ð18Þ
where the first term represents the number of possible combina-
tions of k21 oncogenic mutations from NOL-D unmutated
oncogenes, eRPkmutt’ is the probability of one oncogenic locus
being mutated in the time t’ (given that any hyperproliferative
mutation increases the mutation rate per wild type cell generation
by a factor eRP), and eRPkmutt’
   k 1
is the probability of k21
oncogenic loci being independently mutated in this time, and
PC,k{1,t’~
NOL{D{Kz1
C{D{Kz1
 !
eRpakmut T{t{t’ ðÞ
   C{D{kz1
:
ð19Þ
The number of cells with C21 oncogenic mutations at time T
by non-mutator pathways is the same as in case 2.
As in cases 1 and 2, we use the number of cells with C21
oncogenic mutations to calculate the instantaneous rate of
malignant initiation events at any time, integrating that from 0
to T to obtain the number of initiation events at or prior to T. Nrel,
the relative number of clinical cancers due to mutator compared to
non-mutator pathways at time T or earlier, is again given by the
ratio of total number of malignant initiation events at or before
time T for mutator divided by non-mutator pathways (see
equation [4]). a50% is again derived by setting Nrel=1.
An approximate expression for a50%, in the limit of significant
lineage expansion, and increasingly accurate as the fitness
advantage R and the fold mutation rate increase a get larger,
is:
a50%~
C{D
NMLeRpkmutT
   1
C{D
: ð20Þ
Nrel is given by:
Nrel~
a
a50%
hi C{D
: ð21Þ
In the case of cooperative lineage expansion, we can determine
whether an early or late mutator mutation is more efficient by
comparing the respective values of Nrel. A late mutator (case 3) is
more efficient (and therefore more likely) than an early mutator
(case 2) if and only if:
eRpT aC{Dz1{1
  
C{D
w
aCz1{aC{Dz1
R
: ð22Þ
For a&1, [22] is well approximated by the simple expression:
eRpRT
C{D
waD: ð23Þ
We see that early mutator mutations (i.e. before the fitness
increase) are much more likely in the cooperative case for larger
values of D.
Case 4: Negative Clonal Selection
In this case, lineages are subject to negative clonal selection
(NCS), or random dominant reduced fitness (RF) mutations that
are deleterious with a certain probability proportional to NRFLN-D.
Lineages with reduced fitness become extinct. The loss of fitness is
described by a first order differential equation, leading to
exponential decay of surviving lineages (PS is the probability of
survival), with exponent given by minus the product of the
susceptibility constant b, the number 2 (given diploid cells), a (for
mutator lineages only) and the number of cell generations T. In
turn, b is the product of the mutation rate constant kmut and the
net number of dominant RF loci
NRFLN-D [17]:
PS~e{2bT, ð24aÞ
PS{mut~e{2abT, ð24bÞ
b~kmutNRFLN-D: ð24cÞ
(17)
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be expressed in terms of probabilities rather than expectation
values.
The probability of a malignant lineage initiation by a non-
mutator pathway by time T, Pcancer, 0, NCS, is the product of the
probability of surviving negative clonal selection for T cell
generations (equation [24a]) and the probability of having C
oncogenic mutations at time T [15]:
Pcancer,0,NCS~e{2bT NOL
C
  
kmutT ðÞ
C: ð25Þ
The maximum probability of malignancy as a function of
underlying mutation rate can be found by differentiating this
expression with respect to the mutation rate kmut (bearing in mind
equation [24c] for b), and setting this derivative equal to zero,
leading to equation [1] from the ‘‘Results’’ section. The optimal
mutation rate for carcinogenesis calculated in this way is generally
significantly higher than the wild type mutation rate. The
derivation is analogous to that derived from quasispecies theory
[28–29], except it considers the need to acquire C mutations
rather than 1, T cell generations rather than 1, NRFLN-D rather
than the full genome length as the size of the target which can
mutate to reduced fitness, and the factor of 2 to account for a
diploid genome.
The mutator pathway probability of carcinogenesis is evaluated
assuming the mutator mutation occurs first. Loss of lineages due to
NCS is more rapid after a mutator mutation, but so is the
acquisition of oncogenic mutations. The probability of malignant
lineage initiation with a mutator mutation as step 1, Pcancer, 1, NCS,
is the integral from t equals 0 to T of the product of the
instantaneous rate of occurrence of the mutator mutation at time t
(NML kmut dt); the probability of surviving negative clonal selection
until time t without a mutator mutation, P0, t, NCS; and the
probability of acquiring C oncogenic mutations while surviving
negative clonal selection in time T–t after enhancement of
mutation rate by an mutator mutation, PC-mut, 0, t, NCS:
Pcancer,1,NCS ~
ð T
0
P0,t,NCS PC{mut,0,t,NCS NML kmut dt: ð26Þ
The probability of surviving negative clonal selection until time
t, P0, t, NCS, is given by [24a] and [24c] with T=t. The probability
of acquiring C oncogenic mutations while surviving negative
clonal selection in time T–t after enhancement of mutation rate by
a mutator mutation, PC-mut, 0, t, NCS, is given by the product of: the
probability of surviving negative clonal selection for T-t cell
generations given a mutator mutation, e
22ab(T2t); the number of
ways to choose C oncogenes from a set of NOL oncogenes,
NOL
C
  
; and the probability of C oncogenic mutations occuring
as independent events in time T2t, [akmut(T2t)]
C:
PC mut,0,t,NCS ~e{2ab T{t ðÞ NOL
C
  
akmut T{t ðÞ ½ 
C: ð27Þ
The relative efficiency or probability (Nrel or Prel) of a mutator
pathway with an initial mutator mutation to that of a non-mutator
pathway in the presence of negative clonal selection is the ratio of
the malignant initiation probabilities for mutator vs. non-mutator
pathways, and is given by:
Prel 1:0,NCS~e{2 a{1 ðÞ bTNMLaCkmutTZ, ð28Þ
where
Z~
C! e2 a{1 ðÞ bT{1
  
2 a{1 ðÞ bT ½ 
Cz1 {
X C
n~1
C!
C{nz1 ðÞ ! 2 a{1 ðÞ bT ½ 
n: ð29Þ
For (a21)bT%1, an alternative expression for Z must be used
to maintain adequate computational precision:
Z~
1z
P ?
n~1
Cz1 ðÞ ! 2 a{1 ðÞ bT ½ 
n
Cz1zn ðÞ !
Cz1
: ð30Þ
Lemmas Required to Reproduce the Derivations in Cases
1–3
To reproduce the derivations above, the following identities
involving factorials are required. Proofs of these identities are
available on request.
X C{1
a~1
{1 ðÞ
C{1{aaq
a! C{1{a ðÞ !
~0 for 1ƒqƒC{2,
~1 for q~C{1,
ð31Þ
X D{1
a~0
{1 ðÞ
D{1{a
C{a ðÞ a! D{1{a ðÞ !
~
C{D ðÞ !
C!
: ð32Þ
Supporting Information
Table S1 a50%: incremental and cooperative lineage expansion
cases (cases 1–3). a50%, the minimum fold increase in mutation
rate at which mutator pathways account for 50% of observed
cancers; C, the number of oncogenic mutations required for
commitment to cancer; D, the number of oncogenic mutations
required for fitness increase in the cooperative lineage
expansion model; e
R, the relative fitness advantage per cell
generation of malignant lineages compared to wild type; RP,
the component of R due to enhanced proliferation rate; kmut,
the wild type mutation rate per nucleotide per cell generation;
T, the number of wild type cell generations at which the
efficiency comparison is made (lineages with hyperproliferative
mutations may have undergone more generations); LE, lineage
expansion; MM, mutator mutation. For the cooperative lineage
expansion case, a50% is determined by the smaller of the two
values (early and late mutator mutation). For the cooperative
lineage expansion case with late mutator mutation, D and RP
are required for the calculation, and we assume in these
examples D=2 and RP<0.5 R. Calculated using equations
[11], [12a–h], [16], and [20] of the main paper, or as
described for the constant fitness model (reference 15, main
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nucleotides, mutation of which may lead to genetic instability,
is 100. The fraction of cancers arising with an initial mutator
mutation causing fold mutation increase a in their pathogenesis
is given by a
C/(a
C+a50%
C).
Found at: doi:10.1371/journal.pone.0005860.s001 (0.11 MB
DOC)
Table S2 a50% for high fitness advantage R (R=2): incremental
and cooperative lineage expansion cases (cases 1–3). a50%, the
minimum fold increase in mutation rate at which mutator
pathways account for 50% of observed cancers; C, the number
of oncogenic mutations required for commitment to cancer; D, the
number of oncogenic mutations required for fitness increase in the
cooperative lineage expansion model; e
R, the relative fitness
advantage per cell generation of malignant lineages compared to
wild type; RP, the component of R due to enhanced proliferation
rate; kmut, the wild type mutation rate per nucleotide per cell
generation; T, the number of wild type cell generations at which
the efficiency comparison is made (lineages with hyperproliferative
mutations may have undergone more generations); LE, lineage
expansion; MM, mutator mutation. For the cooperative lineage
expansion case, a50% is determined by the smaller of the two
values (early and late mutator mutation). For the cooperative
lineage expansion case with late mutator mutation, D and RP are
required for the calculation, and we assume in these examples
D=2 except for when C=2 (in which case we assume D=1) and
RP=1.31 (the maximum contribution to R from enhancing cell
survival is 0.69, equivalent to doubling cell numbers each
generation, and the remainder of R must therefore come from
an increased proliferation rate). Calculated using [11–12a–h],
[16], and [20] of the main paper, and as described (reference 15 of
the main paper) for the constant fitness case, assuming NML, the
number of ‘‘mutator loci’’ in nucleotides, mutation of which may
lead to genetic instability, is 100. The fraction of cancers arising
with an initial mutator mutation causing fold mutation increase a
in their pathogenesis is given by a
C/(a
C+a50%
C).
Found at: doi:10.1371/journal.pone.0005860.s002 (0.10 MB
DOC)
Table S3 Prel 1:0, NCS, Relative Efficiency of Mutator Pathways
During Negative Clonal Selection (Case 4). Prel 1:0, NCS, the ratio
of cancers arising with and without an initial mutator mutation in
their pathogenesis in the presence of negative clonal selection
(NCS); C, the number of oncogenic mutations required for
commitment to cancer; NRFLN-D, the net number of dominant
reduced fitness loci; a, the fold increase in mutation rate due to a
mutator mutation; T, the number of wild type cell generations at
which the efficiency comparison is made (lineages with hyperpro-
liferative mutations may have undergone more generations).
Calculated using equations [28–30] of the main paper, assuming
NML, the number of ‘‘mutator loci’’ in nucleotides, mutation of
which may lead to genetic instability, is 100, and kmut, the wild
type mutation rate per base per cell generation, is 10
211. The
fraction of cancers arising with an initial mutator mutation in their
pathogenesis is given by Prel 1:0, NCS/(1+Prel 1:0, NCS).
Found at: doi:10.1371/journal.pone.0005860.s003 (0.07 MB
DOC)
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